2. Search Result
Search Result
Results for "

antinecroptotic

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-169072
    PROTAC MLKL Degrader-2

    		PROTACs Mixed Lineage Kinase Cancer
    PROTAC MLKL Degrader-2 (compound MP-1) is a PROTAC targeting MLKL (Mixed Lineage Kinase). PROTAC MLKL Degrader-2 is composed of PROTAC target protein ligand PROTAC MLKL Degrader-2 (HY-169072) (red part), E3 ligase ligand Thalidomide (HY-14658) (blue part) and PROTAC Linker N-Methylpiperazine (HY-78871) (black part), among which the conjugate of E3 ubiquitin ligase ligand + Linker is Thalidomide-N-methylpiperazine (HY-169074) [1] .
    PROTAC MLKL Degrader-2
  • HY-146758
    RIPK1-IN-14

    		RIP kinase Neurological Disease Inflammation/Immunology
    RIPK1-IN-14 (Compound 41) is a potent inhibitor of RIPK1 with an IC50 value of 92 nM. RIPK1-IN-14 shows a significant anti-necroptotic effect in a necroptosis model in U937 cells .
    RIPK1-IN-14
  • HY-169074
    Thalidomide-N-methylpiperazine

    		E3 Ligase Ligand-Linker Conjugates Cancer
    Thalidomide-N-methylpiperazine is an E3 Ligase Ligand-Linker Conjugate. Thalidomide-N-methylpiperazine can be used to synthesize PROTAC MLKL Degrader-2 (HY-169072) to exhibit antinecroptotic activity on human cell lines and effectively degrade MLKL in the HT-29 xenograft mouse model .
    Thalidomide-N-methylpiperazine
  • HY-157963
    RIPK1-IN-23

    		RIP kinase Necroptosis Inflammation/Immunology Cancer
    RIPK1-IN-23 (compound 19) is a RIPK1 inhibitor with potent anti-necroptotic effects in HT-29 cells (EC50 of 1.7 nM). RIPK1-IN-23 shows anti-inflammatory activities .
    RIPK1-IN-23
  • HY-149052
    SZM-1209

    		RIP kinase Mixed Lineage Kinase Necroptosis Inflammation/Immunology
    SZM-1209 is an orally active, potent and specific RIPK1 inhibitor, with a Kd of 85 nM. SZM-1209 exhibits high anti-necroptotic activity (EC50=22.4 ± 8.1 nM). SZM-1209 shows anti-SIRS (systemic inflammatory response syndrome), and anti-ALI (acute lung injury) effects .
    SZM-1209
  • HY-170232
    RIPK1-IN-29

    		RIP kinase Inflammation/Immunology
    RIPK1-IN-29 (Compound 22) is a RIPK1 inhibitor, with an IC50 of 6.9 nM. RIPK1-IN-29 exerts anti-necroptotic (Apoptosis) activity by inhibiting RIPK1. In a TNF-α-induced in vivo inflammation model, at a dose of 10 mg/kg, RIPK1-IN-29 can protect mice from hypothermia and death. RIPK1-IN-29 can be applied to the research field of inflammatory diseases .
    RIPK1-IN-29
  • HY-181944
    RIPK1-IN-40

    		RIP kinase Necroptosis Cancer
    RIPK1-IN-40 (Compound 51) is a RIPK1 inhibitor and anti-necroptotic agent (with an EC50 of 0.07 μM against necroptosis). RIPK1-IN-40 binds to the kinase domain of RIPK1, forms hydrogen bond interactions with Met95, and establishes additional polar contacts with Asp156 to stabilize binding, thereby inhibiting necroptosis. RIPK1-IN-40 can be used for the research of colorectal cancer .
    RIPK1-IN-40
  • HY-179680
    RIPK1-IN-38

    		RIP kinase Necroptosis Mixed Lineage Kinase Lactate Dehydrogenase Interleukin Related Inflammation/Immunology
    RIPK1-IN-38 is an orally active RIPK1 inhibitor with an IC50 value of 27 nM. RIPK1-IN-38 can inhibit the phosphorylation of RIPK1 and its downstream signaling molecules RIPK3 and MLKL. RIPK1-IN-38 exhibits anti-necroptotic activity. RIPK1-IN-38 has excellent anti-inflammatory efficacy in both the SIRS model and GVHD model. RIPK1-IN-38 can be used for the research of inflammatory and immune-related diseases .
    RIPK1-IN-38

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: